Already have a subscription?Sign In
Access All Charts and Data
Access All Charts and Data
Transparently sourced data in visual form, perfect for legitimizing your strategic ideas and thought leadership via internal and external presentations.
May 1, 2024
GLP-1 Market Developments That US Healthcare Professionals Predict Will Happen, April 2024 (% of respondents )
Featured In
Hims & Hers will offer non-FDA-approved GLP-1 weight loss injectionsOzempic, Wegovy significantly reduce risks of major kidney disease eventsEli Lilly files more lawsuits against companies selling knockoff GLP-1 medications Concerns with Hims & Hers’ weight-loss drug program detailed in a new report Eli Lilly’s GLP-1 medications beat out Novo Nordisk’s for weight loss, study finds Pfizer developing once-daily version of its oral GLP-1Hims & Hers appoints longtime Novo executive to its boardHims & Hers doubles down on compounded weight loss drugs Kourtney Kardashian’s Lemme brand launches “all natural GLP-1” weight loss supplementWeightWatchers will start offering compounded GLP-1 weight-loss drugsOver 40% of online pharmacies advertising semaglutide operated illegally in 2023Drugmaker asks FDA to ban compounding pharmacies from making Ozempic’s key ingredientHims’ weight loss TV ad during the Super Bowl garners bad reviews, incites response from Novo NordiskChart Title
GLP-1 Market Developments That US Healthcare Professionals Predict Will Happen, April 2024 (% of respondents )Publication Date
May 1, 2024
Sources
Source information is only available to PRO subscribers.